Urologic Health raises $11 million seed round for catheter-free bladder monitoring technology

Urologic Health, a medical device company developing non-invasive technology for bladder function assessment, has announced the successful close of an $11 million seed financing round to support the development and commercialization of its bladder monitoring platform. The round was led by an undisclosed strategic investor, with participation from Edge Medical Ventures, SHD Partners, Longevity Venture Partners, and other healthcare-focused investors.

The funding will be directed toward clinical validation, the company’s FDA 510(k) regulatory pathway, and initial commercialization efforts in the United States.

Bladder dysfunction conditions, such as overactive bladder, urinary retention, incontinence, and benign prostatic hyperplasia (BPH), affect hundreds of millions of people globally. Despite advances in treatment options, diagnostic procedures in urology often remain invasive and uncomfortable for patients, creating barriers to timely assessment and ongoing monitoring.

Urologic Health is aiming to address that challenge through its niu™ System, a non-invasive urodynamics platform designed to capture clinically meaningful bladder function data without catheterization. The company states that the technology is intended to support more routine, repeatable, and longitudinal monitoring of bladder health.

“Invasive urodynamics remains one of the most significant barriers in modern urological care,” said Adam Yaacov, Co-founder and CEO of Urologic Health. “While treatment options have evolved considerably, the invasive diagnostic process continues to present challenges for patients. Urologic aims to make bladder function assessment easier for clinicians to perform, painless for patients to undergo, and more informative for longitudinal decision-making.”

According to the company, early feasibility studies have demonstrated that the niu System can capture clinically relevant bladder activity non-invasively. The newly secured financing will also support continued product and manufacturing development, alongside the establishment of the company’s headquarters in Jersey City, New Jersey, ahead of its planned U.S. market entry.

“Urologic Health was established through our unique venture creation model, which works together with strategic industry partners to identify needs and address them by bringing together talented entrepreneurs to build high-potential medical device companies,” said Shai Policker, Managing Partner of Edge Medical Ventures and chairman of Urologic Health’s board.

“By combining exceptional engineering talent in Israel with Edge’s operational support, we are able to help companies like Urologic Health move faster through clinical validation, regulatory execution, and early market entry in the United States.”

Urologic Health was co-founded by Adam Yaacov and Dr. Noam Omer, who bring experience in AI-driven medical technologies and data-centric clinical solutions. The company was founded and incubated through MEDX Xelerator, now operating as EdgeLabs, and is part of the Edge Medical Ventures portfolio with operations across the United States and Israel.

Source

PR Newswire

Are you an investor looking for more than just another conference experience?

MedTech World Europe 2026 will feature an exclusive Investors Retreat in Gozo, bringing together investors, founders, and industry leaders for high-level networking and curated discussions in a more private setting. Pre-register now to stay updated on access, programming, and registration details.